The assay employs nanoplasmonics and protein-signal multiplexing in taking aim at early clinical detection of pancreatic ductal adenocarcinoma.
They have also developed an exosome-based test for high volume laboratory applications that was recently licensed by Exosome Diagnostics.
A microfluidic phone attachment developed at Brigham and Women's and Mass General may be the precursor of a fertility assay that men can use in the home.
The partners will use Namocell's Single Cell Dispenser platform for cell sorting and to capture CTCs.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.
